LAVA Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch LVTX and buy or sell other stocks, ETFs, and their options commission-free!About LVTX
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
CEOStephen Allen Hurly, MBA
CEOStephen Allen Hurly, MBA
Employees34
Employees34
HeadquartersUtrecht, Noord-Brabant
HeadquartersUtrecht, Noord-Brabant
Founded2016
Founded2016
Employees34
Employees34
LVTX Key Statistics
Market cap45.77M
Market cap45.77M
Price-Earnings ratio-2.02
Price-Earnings ratio-2.02
Dividend yield—
Dividend yield—
Average volume138.76K
Average volume138.76K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$2.00
52 Week high$2.00
52 Week low$0.8502
52 Week low$0.8502
Stock Snapshot
With a market cap of 45.77M, LAVA Therapeutics(LVTX) trades at $1.74. The stock has a price-to-earnings ratio of -2.02.
On 2025-12-17, LAVA Therapeutics(LVTX) stock opened at —, reached a high of —, and a low of —.
The LAVA Therapeutics(LVTX)'s current trading volume is 0, compared to an average daily volume of 138.76K.
In the last year, LAVA Therapeutics(LVTX) shares hit a 52-week high of $2.00 and a 52-week low of $0.85.
In the last year, LAVA Therapeutics(LVTX) shares hit a 52-week high of $2.00 and a 52-week low of $0.85.
People also own
Based on the portfolios of people who own LVTX. This list is generated using Robinhood data, and it’s not a recommendation.